The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 9, 1998, Pages 3252-3257

  Grant, Ewan S ^a,c   Ross, Margaret B ^a   Ballard, Stephen ^b   Naylor, Alasdair ^b   Habib, Fouad K ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; BINDING COMPETITION; BINDING SITE; CELL GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

EID: 0031773251     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.9.5119     Document Type: Article

References (35)

1. Rubin R, Baserga R. 1995 Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis and tumorigenicity. Lab Invest 73:311-331.
2. Goldring MB, Goldring SR. 1991 Cytokines and cell growth control. Eukar Gene Express. 1:301-326.
3. Cohick WS, Clemmons DR. 1993 The insulin-like growth factors. Annu Rev Physiol 55:131-153.
4. Pietrzkowski Z, Lammers R, Carpenter G, et al. 1992 Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor I receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ. 3:199-205.
5. Furlanetto RW, DiCarlo JN, Wisehart C. 1987 The type II insulin-like growth factor receptor does not mediate deoxyribonucleic acid synthesis in human fibroblasts. J Clin Endocrinol Metab 64:1142-1144.
6. Kiess W, Haskell JF, Lee L, et al. 1987 An Ab that blocks insulin-like growth-factor (IGF) binding to the type II IGF receptor is neither an agonist or an inhibitor of IGF-stimulated biological responses in L6 myoblasts. J Biol Chem. 262:12745-12751.
7. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. 1994 Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 54:4848-4850.
8. Resnicoff M, Coppola D, Sell C, et al. 1995 The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55:2463-2469.
9. D'Ambrosio C, Ferber A, Resnicoff M, Baserga R. 1996 A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 56:4013-4020.
10. Parrizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D. 1997 Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138:1427-1433.
11. Kulik G, Klippel A, Weber MJ. 1997 Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 17:1595-1606.
12. Siegel YI, Zaidel L, Hanmel I, et al. 1990 Morphometric analysis of benign prostatic hyperplasia. Eur Urol. 18:71-73.
13. Shapiro E, Hartanto V, Becich MJ, et al. 1992 The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic BPH. J Urol. 147:1293-1297.
14. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG. 1994 Insulin-like growth factor abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 79:1410-1415.
15. Dong G, Rajah R, Vu T, et al. 1997 Decreased expression of Wilm's tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab. 82:2148-2203.
16. Kull FC, Jacobs S, Su YF, Svobuda ME, Van Wyk JJ, Cuatrecasas P. 1983 Monoclonal antibodies to receptor for insulin and somatomedin C. J Biol Chem. 258:6561-6566.
17. B ET receptors by the prostatic epithelium and stroma. J Clin Endocrinol Metab. 82:508-513.
18. Kassen A, Sutkowski DM, Ahn H, Sensibar JA, Kozlowski JM, Lee C. 1996 Stromal cells of the prostate: initial isolation and characterization. Prostate. 28:89-97.
19. Chomczynski P, Saachi N. 1987 Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1622:156-159.
20. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. 1993 Inhibition of growth of prostatic cancer cell lines by peptide analogues, of insulin-like growth factor 1. Cancer Res 53:1102-1106.
21. Pohlmann R, Nagel G, Schmidt B, et al. 1987 Cloning of a cDNA encoding the human cation-dependent mannose typhosphate-specitic receptor. Proc Natl Acad Sci USA. 84:5575-5579.
22. Scatchard G. 1949 The attraction of proteins for small molecules and ions. Ann NY Acad Sci. 51:660-672.
23. Egawa M, Hisazumi H, Uchibayashi T, Tanaka M, Sasaki T. 1993 Comparative study of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and tritiated thymidine in a chemosensitivity test using collagen gel matrix. Urol Res. 21:83-88.
24. Wallenstein S, Zucker CL, Fleiss JL. 1980 Some statistical methods useful in circulation research. Circ Res. 47:1-9
25. Huggins C, Hodges CV. 1941 Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:293-297.
26. Kirby RS. 1994 Medical management of benign prostatic hyperplasia. In: Chisbolm GD, ed. Handbook on benign prostatic hyperplasia. New York: Raven Press; 73-94.
27. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. 1991 Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab. 73:401-407.
28. Iwamura M, Sluss PM, Casamento JB, Cockett ATK. 1993 Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate. 22:243-252.
29. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. 1993 Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I. Cancer Res. 53:1102-1106.
30. Rouleau M, Leger J, Tenniswood M. 1990 Ductal heterogeneity of cytokeratins, gene expression, and cell death in the rat ventral prostate. Mol Endocrinol 4:2003-2013.
31. Dunn SE, Hardman RA, Kari FW, Barrett JC. 1997 Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 57:2687-2693.
32. Rouyer-Fessard C, Gammeltoft S, Laburthe M. 1990 Expression of two types of receptor for insulinlike growth factors in human colonic epithelium. Gastroenterology. 98:703-707.
33. Rohlik QT, Adams D, Kull Jr FC, Jacobs S. 1987 An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun. 149:276-281.
34. Zia F, Jacobs S, Kull Jr F, Cuttitta F, Mulshine JL, Moody TW. 1996 Monoclonal antibody αIR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem. 24(Suppl):269-275.
35. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. 1995 Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 95:1897-1905.